Key result
Acellular tissue-engineered vessels maintain 100% patency at 6 months as CABG conduits in primates.
Why the study?
Does a small diameter acellular tissue-engineered vessel (sdATEV) maintain patency and remodel appropriately when used as a coronary artery bypass graft in an adult baboon model?
Does a small diameter acellular tissue-engineered vessel (sdATEV) maintain patency and remodel appropriately when used as a coronary artery bypass graft in an adult baboon model?
Answers are grounded in this paper and cite their sources.
Acellular tissue-engineered vessels demonstrated 100% patency and adaptive host-cell remodeling over 6 months in a primate CABG model, highlighting their potential as an alternative bypass conduit.
Coronary artery bypass graft (CABG) uses the patient's internal mammary artery and saphenous vein; however, unavailable or poor quality autologous vessels limit revascularization. This study addresses the critical need for alternative CABG conduits by evaluating a small diameter acellular tissue-engineered vessel ([sdATEV], 3.5 mm) in a primate model. Adult baboons (n = 5) underwent CABG to the right coronary artery (RCA) with an sdATEV. Patency, diameter, and cardiac function were longitudinally assessed by computed tomography angiography. All sdATEVs remained patent throughout the 6-month study. Computed tomography angiography demonstrated that the distal sdATEV diameter gradually remodeled to approximate the smaller baboon RCA. Histology and spatial transcriptomics revealed that sdATEVs recellularized with host endothelial and smooth muscle cells including a quiescent neomedia layer with gene expression patterns similar to the RCA, indicating that host cell ingrowth from the bypassed coronary artery regulates sdATEV diameter. These results suggest that the sdATEV is a durable alternative CABG conduit.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2025) studied Coronary artery bypass graft (CABG) (n=5). Small diameter acellular tissue-engineered vessel (sdATEV, 3.5 mm) was evaluated on Patency, diameter, and cardiac function. Small diameter acellular tissue-engineered vessels (sdATEVs) used for coronary artery bypass grafting in baboons remained 100% patent throughout the 6-month study.
Synapse has enriched 10 related papers. Consider them for comparative context: